Optimizing doxepin therapy in dermatology: introducing blood level monitoring and genotype testing

References

• Grundmann S, Ständer S. Chronic pruritus: clinics and treatment. Ann Dermatol. 2011;23(1):1–11.
   PubMed Web of Science ®Google Scholar
• Ständer S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol. 2007;87(4):291–294.
   PubMed Web of Science ®Google Scholar
• Kini SP, DeLong LK, Veledar E, et al. The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol. 2011;147(10):1153–1156.
   PubMedGoogle Scholar
• Bickers DR, Lim HW, Margolis D, et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006;55(3):490–500.
   PubMed Web of Science ®Google Scholar
• Nowak D, Yeung J. Diagnosis and treatment of pruritus. Can Fam Physician. 2017;63(12):918–924.
   PubMed Web of Science ®Google Scholar
• Richelson E. Tricyclic antidepressants and histamine H1 receptors. Mayo Clin Proc. 1979;54(10):669–674.
   PubMed Web of Science ®Google Scholar
• Beck KM, Yang EJ, Koo J. Dose escalation of doxepin for intractable pruritus. J Am Acad Dermatol. 2018;79(3):e37.
   PubMed Web of Science ®Google Scholar
• Goldsobel AB, Rohr AS, Siegel SC, et al. Efficacy of doxepin in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1986;78(5):867–873.
   PubMed Web of Science ®Google Scholar
• Almasi A, Meza CE. Doxepin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019. [cited 2019 Dec 9]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK542306/
   Google Scholar
• Figueiredo A, Ribeiro CF, Gonçalo M, et al. Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol. 1990;4(2):147–158.
   PubMed Web of Science ®Google Scholar
• Groene D, Martus P, Heyer G. Doxepin affects acetylcholine induced cutaneous reactions in atopic eczema. Exp Dermatol. 2001;10(2):110–117.
   PubMed Web of Science ®Google Scholar
• Smith PF, Corelli RL. Doxepin in the management of pruritus associated with allergic cutaneous reactions. Ann Pharmacother. 1997;31(5):633–635.
   PubMed Web of Science ®Google Scholar
• Pour-Reza-Gholi F, Nasrollahi A, Firouzan A, et al. Low-dose doxepin for treatment of pruritus in patients on hemodialysis. Iran J Kidney Dis. 2007;1(1):34–37.
   PubMedGoogle Scholar
• Greene SL, Reed CE, Schroeter AL. Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria. J Am Acad Dermatol. 1985;12(4):669–675.
   PubMed Web of Science ®Google Scholar
• Shohrati M, Davoudi S-M, Keshavarz S, et al. Cetirizine, doxepine, and hydroxyzine in the treatment of pruritus due to sulfur mustard: a randomized clinical trial. Cutan Ocul Toxicol. 2007;26(3):249–255.
   PubMed Web of Science ®Google Scholar
• Simons KJ, Watson WT, Chen XY, et al. Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. Clin Pharmacol Ther. 1989;45(1):9–14.
   PubMed Web of Science ®Google Scholar
• Paton DM, Webster DR. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet. 1985;10(6):477–497.
   PubMed Web of Science ®Google Scholar
• Haufroid V, Hantson P. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants. Clin Toxicol. 2015;53(6):501–510.
   PubMed Web of Science ®Google Scholar
• Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008;83(2):234–242.
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Tricyclic antidepressants: the whys and hows of therapeutic drug monitoring. J Clin Psychiatry. 1989;50(Suppl):34–42.
   PubMedGoogle Scholar
• Lavery M, Stull C, Kinney M, et al. Nocturnal pruritus: the battle for a peaceful night’s sleep | Kopernio [Internet]. [cited 2020 Feb 9]. Available from: https://kopernio.com/viewer?doi=https://doi.org/10.3390/ijms17030425&token=WzEzNjc0MTcsIjEwLjMzOTAvaWptczE3MDMwNDI1Il0.osOZe3SbWifB7fug1cs-M0YlfEI.
   Google Scholar
• Tey HL, Wallengren J, Yosipovitch G. Psychosomatic factors in pruritus. Clin Dermatol. 2013;31(1):31–40.
   PubMed Web of Science ®Google Scholar
• Caccavale S, Bove D, Bove RM, et al. Skin and brain: itch and psychiatric disorders. G Ital Dermatol Venereol. 2016;151(5):525–529.
   PubMed Web of Science ®Google Scholar
• Bui Q-U, Ostir GV, Kuo Y-F, et al. Relationship of depression to patient satisfaction: findings from the barriers to breast cancer study. Breast Cancer Res Treat. 2005;89(1):23–28.
   PubMed Web of Science ®Google Scholar
• Filaković P, Biljan D, Petek A. Depression in dermatology: an integrative perspective. Psychiatr Danub. 2008;20(3):419–425.
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK, Schork NJ, et al. Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med. 1994;56(1):36–40.
   PubMed Web of Science ®Google Scholar
• Krause L, Shuster S. Mechanism of action of antipruritic drugs. Br Med J Clin Res Ed. 1983;287(6400):1199–1200.
   PubMedGoogle Scholar
• Rudorfer MV, Potter WZ. Metabolism of tricyclic antidepressants. Cell Mol Neurobiol. 1999;19(3):373–409.
   PubMed Web of Science ®Google Scholar
• Potter WZ, Zavadil AP, Kopin IJ, et al. Single-dose kinetics predict steady-state concentrations of imipramine and desipramine. Arch Gen Psychiatry. 1980;37(3):314–320.
   PubMed Web of Science ®Google Scholar
• Hammer W, Sjöqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci. 1967;6(17):1895–1903.
   PubMedGoogle Scholar
• Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(01/02):9–62.
   PubMed Web of Science ®Google Scholar
• Negrusz A, Moore CM, Perry JL. Detection of doxepin and its major metabolite desmethyldoxepin in hair following drug therapy. J Anal Toxicol. 1998;22(6):531–536.
   PubMed Web of Science ®Google Scholar
• Rao ML, Deister A, Laux G, et al. Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with nonresponse. Pharmacopsychiatry. 1996;29(03):97–102.
   PubMedGoogle Scholar
• Haritos VS, Ghabrial H, Ahokas JT, et al. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics. 2000;10(7):591–603.
   PubMedGoogle Scholar
• Hicks JK, Sangkuhl K, Swen JJ, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37–44.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Henckel H-B, Franke L, et al. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet Genomics. 2005;15(8):579–587.
   PubMed Web of Science ®Google Scholar
• Bogaert MG, Rosseel MT, Deberdt R, et al. Plasma levels of the cis- and trans-isomers of doxepin and desmethyldoxepin after administration of doxepin to patients. Arzneimittelforschung. 1981;31(1):113–115.
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Meineke I, Müller G, et al. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002;12(7):571–580.
   PubMedGoogle Scholar
• Ziegler VE, Biggs JT, Wylie LT, et al. Doxepin kinetics. Clin Pharmacol Ther. 1978;23(5):573–579.
   PubMed Web of Science ®Google Scholar
• Pinder RM, Brogden RN, Speight TM, et al. Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs. 1977;13(3):161–218.
   PubMed Web of Science ®Google Scholar
• Dean L, et al. Amitriptyline Therapy and CYP2D6 and CYP2C19 Genotype. In: Pratt VM, McLeod HL, Rubinstein WS, Scott SA, Dean LC, Kattman BL, editors. Medical genetics summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012. [cited 2020 Feb 25]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK425165/
   Google Scholar
• CYP2D6 - GTR - NCBI [Internet]. [cited 2020 Feb 25]. Available from: https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=cyp2d6.
   Google Scholar
• CYP2C19 - GTR - NCBI [Internet]. [cited 2020 Feb 25]. Available from: https://www.ncbi.nlm.nih.gov/gtr/all/tests/?term=CYP2C19.
   Google Scholar
• Vormfelde SV, Brockmöller J, Bauer S, et al. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin Pharmacol Ther. 2009;86(1):54–61.
   PubMed Web of Science ®Google Scholar
• Crews K, Gaedigk A, Dunnenberger H, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012;91(2):321–326.
   PubMed Web of Science ®Google Scholar
• Genelex - Self Service Portal [Internet]. [cited 2020 Mar 9]. Available from: https://app.genelex.com/self-signup/patient-account.
   Google Scholar
• Meyer-Barner M, Meineke I, Schreeb KH, et al. Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach. Eur J Clin Pharmacol. 2002;58(4):253–257.
   PubMed Web of Science ®Google Scholar
• Güzey C, Norström A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit. 2002;24(3):436–437.
   PubMed Web of Science ®Google Scholar
• Unterecker S, Reif A, Hempel S, et al. Interaction of valproic acid and the antidepressant drugs doxepin and venlafaxine: analysis of therapeutic drug monitoring data under naturalistic conditions. Int Clin Psychopharmacol. 2014;29(4):206–211.
   PubMed Web of Science ®Google Scholar
• Schmid Y, Navarini A, Thomas Z-R, et al. Sex differences in the pharmacology of itch therapies-a narrative review. Curr Opin Pharmacol. 2019;46:122–142.
   PubMed Web of Science ®Google Scholar
• Ständer S, Stumpf A, Osada N, et al. Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden. Br J Dermatol. 2013;168(6):1273–1280.
   PubMed Web of Science ®Google Scholar
• Stumpf A, Ständer S, Warlich B, et al. Relations between the characteristics and psychological comorbidities of chronic pruritus differ between men and women: women are more anxious than men. Br J Dermatol. 2015;172(5):1323–1328.
   PubMed Web of Science ®Google Scholar
• Rubinow DR, Moore M. Sex-dependent modulation of treatment response. Dialogues Clin Neurosci. 2004;6(1):39–51.
   PubMedGoogle Scholar
• Wadelius M, Darj E, Frenne G, et al. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther. 1997;62(4):400–407.
   PubMed Web of Science ®Google Scholar
• Unterecker S, Riederer P, Proft F, et al. Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions. J Neural Transm. 2013;120(8):1237–1246.
   PubMed Web of Science ®Google Scholar
• Hicks JK, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127–134.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25(4):193–200.
   PubMed Web of Science ®Google Scholar
• Ghiculescu RA. Therapeutic drug monitoring: which drugs, why, when and how to do it. [cited 2020 Jan 4]. Available from: https://www.nps.org.au/australian-prescriber/articles/therapeutic-drug-monitoring-which-drugs-why-when-and-how-to-do-it.
   Google Scholar
• Liau MM, Oon HH. Therapeutic drug monitoring of biologics in psoriasis [Internet]. Biologics: targets and therapy. 2019. [cited 2020 Jan 10]. Available from: https://www.dovepress.com/therapeutic-drug-monitoring-of-biologics-in-psoriasis-peer-reviewed-fulltext-article-BTT.
   Google Scholar
• Müller MJ, Dragicevic A, Fric M, et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry. 2003;36(3):98–104.
   PubMed Web of Science ®Google Scholar
• Leucht S, Steimer W, Kreuz S, et al. Doxepin plasma concentrations: is there really a therapeutic range? J Clin Psychopharmacol. 2001;21(4):432–439.
   PubMed Web of Science ®Google Scholar
• Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice. Clin Pharmacokinet. 1999;37(2):147–165.
   PubMed Web of Science ®Google Scholar
• Hendset M, Haslemo T, Rudberg I, et al. The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry. 2006;39(04):121–127.
   PubMedGoogle Scholar